DRTS Earnings & Financial Statements
Alpha Tau Medical Ltd.
$13.40
-$0.11(-0.78%)
39
Overall
--
Value
40
Tech
39
Quality
Market Cap
$1.25B
Volume
171.53K
52W Range
$3.43 - $15.79
Target Price
$18.00
DRTS earnings and financial statements: Alpha Tau Medical Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DRTS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$42.29M | -$36.04M | -$35.68M | -$32.14M | -$13.79M |
| EBITDA | -$41.06M | -$34.94M | -$41.15M | -$32.76M | $28.04M |
| Net income | -$42.63M | -$40.33M | -$42.20M | -$33.76M | -$309.0K |
| EPS (diluted) | $-0.53 | $-0.53 | $-0.42 | $-0.53 | $-0.67 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $105.65M | $86.20M | $107.39M | $120.15M | $42.22M |
| Total liabilities | $28.55M | $23.54M | $22.91M | $14.49M | $23.03M |
| Shareholders’ equity | $77.10M | $62.67M | $84.47M | $105.66M | -$34.78M |
| Cash and equivalents | $12.20M | $13.72M | $12.66M | $6.69M | $23.85M |
| Long-term debt | $6.35M | $5.56M | $5.61M | $4.52M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$26.68M | -$19.78M | -$17.96M | -$23.88M | -$11.81M |
| Capital expenditure | - | - | - | -$904.0K | -$2.93M |
| Free cash flow | -$32.76M | -$22.02M | -$24.36M | -$24.78M | -$14.74M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DRTS | $13.40 | -0.8% | 171.53K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |